Evidence map›Paper›PMID 37206894›Full record

ArticleDigital biomarkers

Reverse Engineering of Digital Measures: Inviting Patients to the Conversation.

Ieuan Clay, Nele Peerenboom, Dana E Connors, Steven Bourke, Alison Keogh, Katarzyna Wac, Tova Gur-Arie, Justin Baker, Christopher Bull, Andrea Cereatti and 27 more

Open access · goldAbstract read
In one paragraph

Article in Digital biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Digital and precision clinical trials: innovations for testing mental health medications, devices, and psychosocial treatments.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 8 countries.

Ieuan ClayVivoSense Inc., Newport Beach, CA, USA.
Nele PeerenboomVivoSense Inc., Newport Beach, CA, USA.
Dana E ConnorsThe Foundation for the NIH, North Bethesda, MD, USA.
Steven BourkePersonalPulse GmbH, Basel, Switzerland.
Alison KeoghInsight Centre for Data Analytics, UC Dublin, Dublin, Ireland.
Katarzyna WacQuality of Life Lab, University of Geneva, Geneva, Switzerland.
Tova Gur-ArieMobilise-D, Newcastle University, Newcastle upon Tyne, UK.
Justin BakerHarvard Medical School, Cambridge, MA, USA.
Christopher BullNewcastle University, Newcastle, UK.
Andrea CereattiMobilise-D, Newcastle University, Newcastle upon Tyne, UK.
Francesca CormackIDEA-FAST, Newcastle University, Newcastle upon Tyne, UK.
Damien EggenspielerSysnav Healthcare, Vernon, France.
Luca FoschiniSage Bionetworks, Seattle, WA, USA.
Raluca GaneaSHL Medical, Zug, Switzerland.
Peter M A GroenenIdorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
Nicole GussetSMA Schweiz, Heimberg, Switzerland.
Elena IzmailovaKoneksa Health, New York, NY, USA.
Christoph M KanzlerBiogen Digital Health International GmbH, Baar, Switzerland.
Lada LeyensF. Hoffmann-La Roche, Basel, Switzerland.
Kate LydenVivoSense Inc., Newport Beach, CA, USA.
Arne MuellerMobilise-D, Newcastle University, Newcastle upon Tyne, UK.
Julian NamF. Hoffmann-La Roche, Basel, Switzerland.
Wan-Fai NgNewcastle University, Newcastle, UK.
David NobbsIDEA-FAST, Newcastle University, Newcastle upon Tyne, UK.
Foteini OrfaniotouF. Hoffmann-La Roche, Basel, Switzerland.
Thanneer Malai PerumalF. Hoffmann-La Roche, Basel, Switzerland.
Wojciech PiwkoTakeda Pharmaceuticals International, Zurich, Switzerland.
Anja RiesF. Hoffmann-La Roche, Basel, Switzerland.
Alf ScotlandBiogen Digital Health International GmbH, Baar, Switzerland.
Nick TaptiklisIDEA-FAST, Newcastle University, Newcastle upon Tyne, UK.
John TorousHarvard Medical School, Cambridge, MA, USA.
Beatrix VereijkenMobilise-D, Newcastle University, Newcastle upon Tyne, UK.
Shuai XuSibel Health, Niles, IL, USA.
Laurenz BaltzerSwiss Federal Institute of Technology, Zurich, Switzerland.
Thorsten VetterEuropean Medicines Agency, Amsterdam, The Netherlands.
Jörg GoldhahnSwiss Federal Institute of Technology, Zurich, Switzerland.
Steven C HoffmannThe Foundation for the NIH, North Bethesda, MD, USA.
Roche (Switzerland) · CHHoag Memorial Hospital Presbyterian · USNewcastle University · GBBiogen (Switzerland) · CHCambridge Cognition (United Kingdom) · GBÉcole Polytechnique Fédérale de Lausanne · CHFoundation for the National Institutes of Health · USHarvard University · USDublin City University · IEEuropean Medicines Agency · NLIdorsia (Switzerland) · CHNorwegian University of Science and Technology · NONovartis (Switzerland) · CHPolitecnico di Torino · ITSage Bionetworks · USSHL Medical (Switzerland) · CHSibel (United States) · USSysnav (France) · FRTakeda (Switzerland) · CHUniversity of Geneva · CH

Funding

Wellcome Trust
6 · The paper itself

Abstract

Background: Digital measures offer an unparalleled opportunity to create a more holistic picture of how people who are patients behave in their real-world environments, thereby establishing a better connection between patients, caregivers, and the clinical evidence used to drive drug development and disease management. Reaching this vision will require achieving a new level of co-creation between the stakeholders who design, develop, use, and make decisions using evidence from digital measures. Summary: In September 2022, the second in a series of meetings hosted by the Swiss Federal Institute of Technology in Zürich, the Foundation for the National Institutes of Health Biomarkers Consortium, and sponsored by Wellcome Trust, entitled "Reverse Engineering of Digital Measures," was held in Zurich, Switzerland, with a broad range of stakeholders sharing their experience across four case studies to examine how patient centricity is essential in shaping development and validation of digital evidence generation tools. Key Messages: In this paper, we discuss progress and the remaining barriers to widespread use of digital measures for evidence generation in clinical development and care delivery. We also present key discussion points and takeaways in order to continue discourse and provide a basis for dissemination and outreach to the wider community and other stakeholders. The work presented here shows us a blueprint for how and why the patient voice can be thoughtfully integrated into digital measure development and that continued multistakeholder engagement is critical for further progress.

Indexed as

Co-creationDigital measuresMeeting reportMultistakeholder engagementPatient centricity

Identifiers

PMID37206894
PMCPMC10189241
OpenAlexW4377142679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.